How I Treat HLH-Like Toxicities Following Immune Effector Cell Therapy - PubMed
12 hours ago
- #CAR T-cell therapy
- #HLH-like toxicities
- #cancer immunotherapy
- Breakthroughs in cancer immunotherapy have introduced new treatments like checkpoint inhibitors, CAR T-cells, and bispecific T-cell engagers.
- Therapy-related HLH-like toxicities are part of hyperinflammatory syndromes, including Immune effector cell-associated HLH-like syndrome (IEC-HS).
- IEC-HS is distinct from cytokine release syndrome (CRS), often emerging after CRS subsides or resolves.
- CRS with multiorgan dysfunction (CRS-MOD) shows HLH-like manifestations with worsening CRS and may not respond to standard CRS therapy.
- Differentiating HLH-like syndromes is challenging but crucial due to their association with poor outcomes.
- Early recognition, comprehensive diagnostics, and intervention strategies can improve patient outcomes.
- The article discusses managing CAR-associated HLH-like syndromes (CRS-MOD and IEC-HS) and current treatment approaches.